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ABSTRACT
To clarify the molecular and clinicopathological characteristics of colorectal 
serrated lesions, we assessed the DNA methylation of cancer-associated genes in a 
cohort of BRAF-mutant precancerous lesions from 94 individuals. We then compared 
those results with the lesions’ clinicopathological features, especially colorectal 
subsites. The lesions included hyperplastic polyps (n = 16), traditional serrated 
adenomas (TSAs) (n = 15), TSAs with sessile serrated adenomas (SSAs) (n = 6), 
SSAs (n = 49) and SSAs with dysplasia (n = 16). The prevalence of lesions exhibiting 
the CpG island methylator phenotype (CIMP) was lower in the sigmoid colon and 
rectum than in other bowel subsites, including the cecum, ascending, transverse 
and descending colon. In addition, several cancer-associated genes showed higher 
methylation levels within lesions in the proximal to sigmoid colon than in the sigmoid 
colon and rectum. These results indicate that the methylation status of lesions with 
BRAF mutation is strongly associated with their location, histological findings and 
neoplastic pathways. By contrast, no difference in aberrant DNA methylation was 
observed in normal-appearing background colonic mucosa along the bowel subsites, 
which may indicate the absence of an epigenetic field defect.
INTRODUCTION
Recent studies have shown that colorectal cancers 
(CRCs) are heterogeneous diseases that derive from distinct 
molecular pathways [1, 2]. A large proportion (80-85%) of 
sporadic CRCs develop through accumulation of multiple 
genetic and epigenetic alterations, including mutation of 
oncogenes and tumor suppressor genes [3], chromosomal 
instability (CIN) and global DNA hypomethylation. The 
remaining 15-20% of sporadic CRCs exhibit microsatellite 
instability (MSI) and concurrent hypermethylation in 
multiple loci, which is referred to as the CpG island 
methylator phenotype (CIMP) [4] and is tightly associated 
with BRAF mutation [5, 6].
Similarly, molecular and clinicopathological 
analysis of colorectal premalignant lesions, including 
conventional adenomas and serrated lesions, has provided 
insight into the development of CRC and its implications 
Oncotarget35107www.impactjournals.com/oncotarget
for prevention and treatment [7]. Since establishment 
of the pathological classification of serrated colorectal 
lesions as hyperplastic polyps (HPs), traditional serrated 
adenomas (TSAs) or sessile serrated adenomas (SSAs) 
[8-11], there have been several investigations of the 
molecular alterations within those lesions. Those studies 
provide evidence that SSAs are associated with BRAF 
mutation and CIMP, and that they are precursors of 
MSI-positive CRCs, which preferentially locate in the 
proximal colon (serrated-neoplasia pathway) [6, 12-14]. 
TSAs are also considered to be premalignant lesions and 
reportedly exhibit BRAF or KRAS mutations and aberrant 
DNA methylation [11, 15-20], though their biological and 
clinical characteristics are not yet fully understood. One 
aim of the present study was to clarify the involvement of 
epigenetic alterations in serrated lesions.
The two-side colon theory was recently challenged 
by the observation that the frequencies of BRAF mutation, 
CIMP and MLH1 methylation in CRCs gradually increase 
along the colon, from the rectum to the ascending colon 
[21]. However, there have been few reported studies 
on the association between colorectal subsites and the 
clinicopathological and molecular characteristics in 
precancerous lesions [22, 23]. In the present study, we also 
assessed the association between DNA methylation status 
and clinicopathological features, including tumor locations 
in early colorectal lesions with BRAF mutation.
Epigenetic fields for cancerization (also known as 
“epigenetic field defects”) have been reported in several 
cancers, including CRC [24]. Since the first report of estrogen 
receptor gene methylation in normal colorectal mucosa [25], 
DNA methylation of a number of genes in normal-appearing 
colorectal mucosa from patients with CRC [26-29] or a 
precursor lesion [29,30] have been evaluated. However, the 
methylation status of the normal mucosa adjacent to serrated 
lesions has not been studied in detail. We therefore addressed 
this issue in BRAF-mutant precursor lesions.
RESULTS
CIMP status and locations of BRAF-mutant 
lesions
The clinicopathological and molecular characteristics 
of the early colorectal lesions with BRAF mutation analyzed 
in this study are summarized in Tables 1 and 2. The majority 
(74/106, 69.8%) of these lesions were located in the right 
colon (from the cecum to the transverse colon), while 24 
lesions (22.7%) were found in the left colon (descending and 
sigmoid colon), and 8 (7.5%) were in the rectum (Table 1). 
SSAs were predominantly observed in the proximal colon, 
while TSAs were more prevalent in the sigmoid colon and 
rectum (Table 2). The CIMP statuses of the lesions in the 
respective bowel subsites are summarized in Figure 1. 
Notably, CIMP-positive lesions were located predominantly 
in the proximal bowel subsites, from the cecum to the 
descending colon, and were significantly less frequent in the 
sigmoid colon and rectum (Figure 1C). Logistic regression 
analysis confirmed that the correlation between tumor 
location and CIMP status was most significant when the 
bowel was subdivided using the sigmoid-descending colon 
junction as a boundary (Table 3).
Table 1: Clinicopathological features of the BRAF-
mutant lesions in this study
Patients (n=94)
Age (years, mean ± SD) 62.9 ± 11.3
Gender
 Female 36 (38.3%)
 Male 58 (61.7%)
Lesions (n=106)
Location
 Right colon 74 (69.8%)
 Left colon 24 (22.7%)
 Rectum 8 (7.5%)
Bowel subsites
 Cecum 9 (8.5%)
 Ascending colon 37 (34.9%)
 Transverse colon 28 (26.4%)
 Descending colon 7 (6.6%)
 Sigmoid colon 17 (16.0%)
 Rectum 8 (7.6%)
Morphology
 Flat 62 (58.5%)
 Protruded 41 (38.7%)
 Flat+protruded 3 (2.8%)
Histology
 HP/IM 16 (15.1%)
 TSA 15 (14.2%)
 TSA+SSA 6 (5.7%)
 SSA 49 (46.2%)
 SSA+CD 9 (8.5%)
 SSA+HGD 7 (6.6%)
 Conventional adenoma 3 (2.8%)
 HGD 1 (0.9%)
HP, hyperplastic polyp; IM, intermediate; TSA, traditional 
serrated adenoma; SSA, sessile serrated adenoma; CD, 
cytological dysplasia; HGD, high grade dysplasia
Oncotarget35108www.impactjournals.com/oncotarget
We next assessed the relationship between 
CIMP status and the clinicopathological findings 
(Table 2). CIMP was detected more frequently in 
lesions containing SSA components (SSAs, 61.2%; 
SSAs with cytological dysplasia, 66.7%; SSA with 
high-grade dysplasia, 85.7%; TSA with SSAs, 66.7%) 
than in TSAs (26.7%) or HPs/intermediate (IM), which 
is serrated lesions that did not satisfy the criteria for 
SSA or TSA (37.5%) (Figure 2A). Consistent with an 
earlier report [23], we found a tendency for CIMP to be 
more prevalent among larger tumors, though this was 
not statistically significant (Figure 2B).
Table 2: Clinicopathological and molecular characteristics of BRAF-mutant lesions
Total 
number
Proximal colon Distal colon Rectum
Cecum Ascending 
colon
Transverse 
colon
Descending 
colon
Sigmoid 
colon
Patients 94 9 31 25 7 14 8
Age (years, mean ± SD) 62.9 ± 11.3 63.9 ± 8.3 65.8 ± 10.7 65.1 ± 12.9 60.3 ± 6.9 56.1 ± 12.4 65.0 ± 8.7
Sex
 Female 36 (38.3%) 5 13 15 1 2 0
 Male 58 (61.7%) 4 18 10 6 12 8
Lesions 106 9 37 28 7 17 8
Morphology
 Flat 62 (58.5%) 8 28 18 2 4 2
 Protruded 41 (38.7%) 1 8 9 5 13 5
 Flat+protruded 3 (2.8%) 1 1 1
Size (mm, mean ± SD) 10.2 ± 5.6 10.3 ± 5.8 11.7 ± 5.9 11.1 ± 5.8 7.7 ± 1.8 8.2 ± 4.9 6.5 ± 2.1
Histology
 HP/IM 16 (15.1%) 3 3 1 6 3
 TSA 15 (14.2%) 1 1 2 8 3
 TSA+SSA 6 (5.7%) 3 3
 SSA 49 (46.2%) 9 20 14 3 2 1
 SSA+CD 9 (8.5%) 5 4
 SSA+HGD 7 (6.6%) 3 3 1
 Conventional adenoma 3 (2.8%) 1 1 1
 HGD 1 (0.9%) 1
CIMP status
 Positive 57 (53.8%) 5 27 18 4 2 1
 Negative 49 (46.2%) 4 10 10 3 15 7
MLH1 methylation
 Positive 10 (12.9%) 0 3 6 1 0 0
 Negative 96 (87.1%) 9 34 22 6 17 8
Adjacent normal colon 83 8 28 22 7 12 6
HP, hyperplastic polyp; IM, intermediate; TSA, traditional serrated adenoma; SSA, sessile serrated adenoma; 
CD, cytological dysplasia; HGD, high grade dysplasia
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Figure 1: Methylation profiles in BRAF-mutant lesions. A. Methylation of CIMP markers and CIMP status in lesions in the right 
colon (from cecum to transverse colon) and the left colon (from descending colon to sigmoid colon). B. Methylation status in BRAF-mutant 
lesions in the cecum (C) and ascending (A), transverse (T), descending (D) and sigmoid (S) colon and rectum (R). C. Frequencies of CIMP 
and MLH1 methylation in BRAF-mutant lesions in the indicated bowel subsites.
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Methylation of MLH1 is a hallmark of MSI in 
sporadic CRCs. We assessed MSI status in 24 lesions 
and found that the methylation status of MLH1 was 
consistent with the MSI status in 23 of 24 lesions (7 of 
24 were MSI-positive, while 6 were MLH1 methylation-
positive; P < 0.001). We observed MLH1 methylation in 
lesions within the ascending, transverse and descending 
colon, but its frequency was much lower than that of 
CIMP (Figure 1C). Moreover, MLH1 methylation was 
observed much more frequently in SSA+HGDs (85.7%) 
than in other types of lesions (SSA+CDs, 6.7%; SSAs, 
4.1%; TSA+SSAs, 0%; TSAs, 0%; HP/IMs. 0%) 
(Figure 2A). These results are consistent with the 
earlier observations that SSAs are precursor lesions for 
CIMP-positive and MSI-positive CRCs, and that MLH1 
methylation is not an early event during colorectal 
tumorigenesis [6, 31, 32].
Methylation of tumor-related genes in 
BRAF-mutant lesions
We next assessed methylation of the promoter 
CpG islands of genes known to be frequently 
methylated in CRC [14]. We found that the methylation 
levels of CDKN2A, IGFBP7, RASSF2, SOX5, 
GALNT14, miR-34b/c and LRP1B were significantly 
higher in lesions located at bowel subsites from the 
cecum to the descending colon than in lesions in the 
sigmoid colon and rectum, which was consistent with 
the CIMP status (Figure 3, Supplementary Figure S1). 
By contrast, levels of SFRP1 and SFRP2 methylation 
were consistently elevated in lesions throughout the 
entire bowel, indicating that those genes are methylated, 
irrespective of tumor location or the molecular subtype 
of the tumor.
To evaluate global DNA hypomethylation within 
the lesions, we analyzed levels of LINE-1 methylation, 
which did not correlate with bowel location (Figure 3K, 
Supplementary Figure S1K). Nor did levels of LINE-1 
methylation correlate significantly with CIMP status or 
MLH1 methylation (data not shown).
Methylation analysis of adjacent normal-
appearing mucosae
To determine whether an epigenetic field defect is 
involved in the development of BRAF-mutant lesions, 
we collected matched samples of the lesion and normal-
appearing colonic mucosa adjacent to the lesions from 
83 individuals and then assessed the methylation status 
of three selected genes (miR-34b/c, SFRP1 and SFRP2) 
plus LINE-1. We found that methylation levels of the 
three genes were significantly lower in normal colonic 
mucosa than in the corresponding tumors (Supplementary 
Figure S2A–2C, S3A–2C), and that methylation did not 
correlate with location within the bowel (Figure 4A–4C, 
Supplementary Figure S4). In addition, methylation of the 
selected genes in normal-appearing colonic mucosa was 
not associated with the CIMP or MLH1 methylation status 
in the corresponding tumor tissues (Supplementary Figure 
S5A–5C, S6A–6C).
By contrast, levels of LINE-1 methylation were 
lower in the lesions than the adjacent normal-appearing 
colonic mucosa (P = 0.02; Supplementary Figure S2D, 
S3D). Although levels of LINE-1 methylation in the 
normal colon did not correlate with location within the 
bowel or MLH1 methylation (Figure 4D, Supplementary 
Figure S6D), colonic tissues adjacent to CIMP-positive 
lesions exhibited lower LINE-1 methylation levels than 
those adjacent to CIMP-negative lesions (P = 0.04, 
Supplementary Figure S5D). These results suggest 
changes in gene methylation occur in the normal colonic 
mucosa adjacent to tumors, but they do not strongly 
support the existence of an epigenetic field defect.
DISCUSSION
In this study, we comprehensively analyzed BRAF-
mutant colorectal lesions and observed an interesting 
relationship between epigenetic alterations within the 
lesions and their bowel subsite locations. The frequency of 
CIMP-positive lesions significantly differed between the 
proximal and distal colon when the sigmoid-descending 
Table 3: Correlations between tumor location and CIMP status in BRAF-mutant lesions
Demarcation OR (95% CI) P
C-A 1.39 (0.36-5.46) 0.447
A-T 2.9 (1.37-6.13) 0.004
T-D 7.14 (2.81-18.18) 0.000011
D-S 13.89 (3.91-50.00) 0.000001
S-R 9.52 (1.16-76.92) 0.018
C, cecum; A, ascending colon; T, transverse colon; D, descending colon; S, sigmoid colon; R, rectum
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colon junction was used as a borderline. Similarly, levels 
of DNA methylation in RASSF2, SOX5, GALNT14 and 
miR-34b/c, four cancer-related genes, were strikingly 
higher in lesions located in the proximal colon (from the 
cecum to the descending colon) than in those in more 
distal subsites. This probably reflects the higher frequency 
of SSAs (including SSAs with dysplasia and TSAs with 
SSAs) in the region extending from the cecum to the 
descending colon. To prevent progression to CRC, it is 
recommended that all serrated lesions proximal to the 
sigmoid colon be resected during colonoscopy [11]. Our 
results support that recommendation.
Recent studies suggest TSAs represent a heterogeneous 
category containing lesions that developed through at least two 
different neoplastic progression pathways that are distinct from 
the SSA pathway [16, 17]. For instance, the majority of SSAs 
Figure 2: A. Frequencies of CIMP and MLH1 methylation in lesions with the indicated histological findings: HP, hyperplastic polyp; IM, 
intermediate; TSA, traditional serrated adenoma; SSA, sessile serrated adenoma; CD, cytological dysplasia; HGD, high-grade dysplasia. 
B. Frequencies of CIMP and MLH1 methylation in BRAF-mutant lesions with indicated diameters.
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Figure 3: Summaries of the bisulfite pyrosequencing results from BRAF-mutant lesions. Shown are the levels of methylation 
of indicated genes A–H. and LINE-1 I. in lesions in the cecum (C) and ascending (A), transverse (T), descending (D) and sigmoid (S) colon 
and rectum (R). *P < 0.05, **P < 0.01, ***P < 0.001.
Oncotarget35113www.impactjournals.com/oncotarget
exhibit BRAF mutations, while TSAs exhibit KRAS or BRAF 
mutations [16-19]. It is still unclear whether BRAF-mutant 
TSAs and SSAs develop into CRCs via the same neoplastic 
pathway, though one recent study proposed these lesions follow 
the same molecular pathway (BRAF mutation pathway) [17]. 
From the viewpoint of molecular analysis, the combination 
of MAP kinase pathway activation and CIMP is potentially 
strong evidence supporting their continued inclusion [17]. In 
addition, the presence of non-dysplastic precursor lesions (HPs 
or SSAs) associated with TSAs, which is reportedly observed 
in approximately 20-50% of TSAs and is significantly 
associated with BRAF mutation, also supports this idea [17-20]. 
Consistent with earlier reports [17-19], 6 of 21 TSAs (28.5%) 
were associated with SSAs, and all of the lesions were in the 
proximal colon, while 13 of 15 TSAs without precursor lesions 
were located in the distal colon. Our analysis also revealed 
that the prevalence of CIMP in TSA+SSAs was equivalent 
to that in SSAs and SSA+CDs, which could contribute to the 
observed differences in epigenetic alterations in BRAF-mutant 
serrated lesions in different bowel subsites. It is still unclear 
whether TSAs arise from SSAs or whether TSA+SSAs are in 
the same category as SSA+CDs. A recent study showed that 
the SSA marker annexin A10 (ANXA10) is not expressed in 
TSAs or in adjacent SSAs, suggesting the precursor serrated 
polyps associated with TSA differ biologically from SSAs [20]. 
In this study, we also noted that the frequency of CDKN2A 
methylation is higher in SSA+CDs (4 of 9 cases, 44.4%) than 
in TSA+SSAs (1 of 6 cases, 16.7%), though the difference 
was not statistically significant. This suggests methylation 
profiles may differ between the two lesions, though more 
comprehensive analysis of DNA methylation will be required 
to draw a conclusion.
Cumulative evidence suggests BRAF-mutant SSAs are 
precursors of CRCs with MSI, while BRAF-mutant TSAs are 
reportedly precursors of microsatellite-stable (MSS) CRCs 
[16, 17]. In addition, recent studies showed that MSI/BRAF-
Figure 4: Summaries of bisulfite pyrosequencing results in normal-appearing mucosa adjacent to BRAF-mutant 
lesions. Shown are levels of methylation of the indicated genes A–C. and LINE-1 D. in the cecum (C) and ascending (A), transverse (T), 
descending (D) and sigmoid (S) colon and rectum (R).
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mutant CRCs are associated with a favorable prognosis, 
while BRAF-mutant MSS CRCs were associated with a 
poor one [33-35]. These results suggest that the methylation 
status of cancer-related genes and the tumor locations are 
associated with the pathological findings, carcinogenic 
potentials and prognoses of BRAF-mutant lesions.
To assess the involvement of an epigenetic field 
defect in the development of BRAF-mutant lesions, we 
analyzed the DNA methylation status of genes in normal 
colonic mucosa adjacent to the lesions. An et al. reported 
that levels of RASSF1A and SFRP1 methylation in normal-
appearing mucosa from patients with distal CRCs or polyps 
(conventional adenomas) were significantly higher than in 
proximal CRC or polyp patients [29]. In the present study, 
however, we did not observe significant differences in gene 
methylation in normal-appearing colonic mucosa among 
specimens from individuals with lesions in different bowel 
subsites, which is in contrast to the findings of Kawakami 
et al [28]. In addition, Worthley et al. [30] reported that the 
mean CIMP Z-scores calculated from the pancolorectal 
percent of methylated reference (PMR) using a CIMP panel 
(CACNA1G, IGF2, RUNX3, NEUROG1, and SOCS1) in the 
background mucosa of advanced proximal serrated polyps 
(advanced PSPs: >1 cm in diameter or with advanced 
features, including SSA, TSA or mixed polyp) were higher 
than in colonic mucosa with non-advanced PSPs or without 
any polyps. We also compared the methylation levels in the 
background mucosa of advanced PSPs with the levels in 
background mucosa from other types of serrated polyps, but 
we found no significant differences (data not shown). This 
difference between our findings and those of Worthley et al. 
[30] likely reflects differences in the method of methylation 
analysis (MethyLight vs. pyrosequencing), lesions analyzed 
(all serrated lesions vs. BRAF-mutant lesions) and sampling 
locations (pancolorectal vs. adjacent mucosa).
The present study has several limitations, including 
a relatively small sample size, a limited number of 
lesions available for MSI analysis, the absence of normal 
background samples from subjects without lesions, and a 
limited number of genes assessed in the normal-appearing 
background samples. Nonetheless, we were able to make 
several important observations. First, methylation status 
in BRAF-mutant lesions is strongly associated with their 
location, histological findings and neoplastic pathways. 
Second, the methylation profiles in BRAF-mutant lesions 
in the proximal colon may greatly differ from those in 
the distal bowel when the sigmoid-descending colon 
junction is used as a demarcation point. Third, there were 
no significant differences in the methylation levels in 
background normal mucosa from different bowel subsites, 
which may indicate the absence of an epigenetic field 
defect for BRAF-mutant lesions. At present, it remains 
unclear whether SSAs and TSAs with BRAF mutations 
share a common origin. Further study to clarify the 
spectrum of genetic and epigenetic alterations in BRAF-
mutant lesions, including SSAs with or without dysplasia, 
TSAs and TSA+SSAs, will likely provide new insight into 
the molecular mechanisms underlying different neoplastic 
pathways.
MATERIALS AND METHODS
Patients and tissue samples
Biopsy specimens from BRAF-mutant colorectal 
lesions (n = 106) and corresponding noncancerous colonic 
mucosa (n = 83) were obtained from 94 Japanese patients 
who underwent colonoscopic examination at Akita Red 
Cross Hospital (Table 1). Informed consent was obtained 
from all patients before collection of the specimens, and 
approval of this study was obtained from the Institutional 
Review Board of Akita Red Cross Hospital and Sapporo 
Medical University.
Endoscopic analysis
High-resolution magnifying endoscopes (CF260AZI; 
Olympus, Tokyo, Japan) were used for all colonoscopic 
analyses. All lesions detected during colonoscopy were 
observed at high magnification using indigo carmine dye, 
after which biopsy specimens were collected from the 
lesions and adjacent normal-appearing colonic mucosa for 
genomic DNA extraction. The lesions were then treated 
by endoscopic mucosal resection, endoscopic submucosal 
dissection or surgical resection for histological analysis, as 
previously reported [13, 14].
Histological analysis
Histological findings for all specimens were 
evaluated by a pathologist (T.S.) who was blinded to 
the clinical and molecular information. Conventional 
adenoma was diagnosed using the standard criteria. 
Serrated lesions (HPs, SSAs and TSAs) were classified 
based on the criteria previously described by Torlakovic et 
al [9]. Mixed serrated lesions composed of SSA, TSA, CD 
and HGD were evaluated on the basis of each component 
and described as TSA+SSA, SSA+CD or SSA+HGD. The 
clinicopathological features of the lesions are summarized 
in Table 2, and salient histopathological features of the 
major polyp subtypes are shown in Figure 5. Tumor 
locations were classified as cecum, ascending colon, 
transverse colon, descending colon, sigmoid colon and 
rectum (rectosigmoid was classified into sigmoid colon).
Mutation analysis
Genomic DNA was extracted using the standard 
phenol-chloroform procedure. Mutation in codon 600 of 
BRAF was examined by pyrosequencing using a BRAF 
pyro kit (Qiagen, Hiden, Germany) according to the 
manufacturer’s instructions.
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DNA methylation analysis
DNA methylation was analyzed using bisulfite 
pyrosequencing as described previously [36]. Briefly, 
genomic DNA (1 µg) was modified with sodium bisulfite 
using an EpiTect Bisulfite kit (Qiagen). Pyrosequencing 
was then carried out using a PSQ 96MA system (Qiagen) 
with a Pyro Gold Reagent kit (Qiagen), and the results 
were analyzed using Pyro Q-CpG software (Qiagen). 
A cutoff value of 15% was used to define genes as 
methylation-positive. Tumors were defined as CIMP-
positive when methylation was detected in three or more 
Figure 5: Representative histopathological images of the major serrated lesion subtypes. A. Hyperplastic polyp (HP). 
B. Sessile serrated adenoma (SSA). C. Traditional serrated adenoma (TSA). D. TSA with SSA (TSA+SSA). E. SSA with cytological 
dysplasia (SSA+CD). F. SSA with high-grade dysplasia (SSA+HGD).
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loci out of five classic CIMP markers (MINT1, MINT2, 
MINT12, MINT31 and MLH1) and CDKN2A (p16). 
Methylation of LRP1B, SOX5, GALNT14, RASSF2, 
IGFBP7, miR-34b/c, SFRP1, SFRP2 and long interspersed 
nucleotide elements (LINE-1) was also analyzed using 
bisulfite pyrosequencing. Primer sequences were as 
previously reported [14, 37].
MSI analysis
MSI was assessed as described previously [38]. 
MSI status was determined by examining a panel of 5 
microsatellite markers (BAT25, BAT26, D5S346, D2S123, 
D17S250) [39]. Lesions were defined as MSI-positive 
when two or more markers showed instability.
Statistical analysis
Continuous data were analyzed using t-tests (for 
two groups) or ANOVA with a post hoc Tukey’s HSD test 
(for more than two groups). Fisher’s exact test and logistic 
regression were performed to assess the association 
between categorical variables. P < 0.05 was considered 
statistically significant. All statistical analyses were 
performed using SPSS 20 (IBM Corporation, Somers, 
NY) and GraphPad Prism 6 (GraphPad Software, La Jolla, 
CA).
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